Purpose of this Study
We are doing this study to find out if an experimental vaccine is a safe and effective option to protect against H5 avian influenza (bird flu).
Who Can Participate?
Eligibility
Adults ages 18-49 who:
- Are in good general health
- Do not have any form of autoimmune disease
- Do not have regular contact with chickens or cattle
Age Range
18-49
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
Yes
What is Involved?
Description
If you choose to join this study, you will:
- Have a screening visit to confirm your eligibility
- Get 2 doses of the study vaccine about a month apart from each other
- Fill out surveys once a day for 7 days after each vaccination visit
- Visit our clinic up to 5 times for follow-up visits after getting the study vaccine
Locations
Other
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
A Phase 1 Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Antigenically Central (AC)-Anhui mRNA-LNP Vaccine in Healthy Adults
Principal Investigator
Emmanuel
Walter
Protocol Number
PRO00117755
Phase
I
Enrollment Status
Open to Enrollment